Blueprint Medicines (BPMC) shares ended the last trading session 18.2% higher at $103.36. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.2% loss over the past four weeks.The sudden soaring of the stock price was observed after Blueprint announced its 2025 corporate outlook and growth strategy, highlighting plans to build on its established R&D and commercial expertise. Growth in 2025 is expected to be fuelled by ...

BLU-808 Phase 1 Trial Results - BLU-808 demonstrated rapid, robust, and sustained reductions in serum tryptase, exceeding 80% in the Phase 1 healthy volunteer study [6] - Dose-dependent tryptase reductions were observed: 1 mg (-23%), 3 mg (-41%), 6 mg (-66%), and 12 mg (-87%) [2] - BLU-808 showed a wide therapeutic window and was well-tolerated at all doses tested, with no serious adverse events or discontinuations [7][16] Systemic Mastocytosis Franchise Opportunity - The company estimates the peak revenue opportunity for its systemic mastocytosis (SM) franchise at $4 billion, driven by AYVAKIT's strong launch and evolving SM prevalence estimates [6][15] - AYVAKIT revenue is expected to reach $2 billion by 2030 [6][15] - The company plans to achieve reimbursement for AYVAKYT in ≥20 countries by the end of 2025 [3] Pipeline and Strategic Updates - The company is advancing CDK2 and CDK4 targeted protein degraders, prioritizing further investment in its CDK franchise for breast cancer and other solid tumors [3] - The Phase 3 HARBOR trial of elenestinib, a next-generation KIT D816V inhibitor, has been initiated in patients with indolent systemic mastocytosis (ISM) [3] - Proof-of-concept trials for BLU-808 in chronic urticaria, allergic asthma, allergic rhinitis, allergic conjunctivitis, and mast cell activation syndrome are planned for 2025 [8][20] Financial and Corporate Goals - The company expects AYVAKIT product revenue for full-year 2024 to be $475 to $480 million, representing an increase of more than 130% over 2023 [12] - Corporate goals for 2025 include growing franchise leadership in SM and achieving clinical proof-of-concept for BLU-808 in allergic and inflammatory diseases [20] - The company aims to nominate two development candidates, including its first targeted protein degrader, in the second half of 2025 [17] J P Morgan Conference Presentation - Detailed data from the BLU-808 Phase 1 trial will be presented at the J P Morgan conference on January 13, 2025 [1][9] - The CEO will present a company overview and 2025 outlook at the conference, with a live webcast available on the company's website [9]

CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET). A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcast wi ...

It has been about a month since the last earnings report for Blueprint Medicines (BPMC) . Shares have added about 8.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Blueprint Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. BPMC Beats on Q3 Earnings and S ...

Blueprint Medicines Corporation (BPMC) reported third-quarter 2024 adjusted loss of 89 cents per share, narrower than the Zacks Consensus Estimate of a loss of 97 cents. The company had incurred a loss of $2.20 per share in the year-ago quarter.Quarterly revenues of $128.2 million, generated entirely from the net product sales of Ayvakit, surpassed the Zacks Consensus Estimate of $126 million. Total revenues jumped 127% year over year. Ayvakit sales have increased 136% year over year, driven by new patient ...

Table of Contents _____________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________ FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37359 _____________________________ BLUEPRINT MEDICINES CORPORATION (Exact Name of ...

Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Christy Rossi - Chief Operating Officer Mike Landsittel - Chief Financial Officer Fouad Namouni - President-Research & Development Conference Call Participants Marc Frahm - TD Cowen Brad Canino - Stifel Reni Benjamin - Citizens JMP Paul Jeng - Guggenheim To ...

Blueprint Medicines (BPMC) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $2.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 8.25%. A quarter ago, it was expected that this cancer drug developer would post a loss of $1.28 per share when it actually produced a loss of $0.80, delivering a surprise of 37.50%. Over the last four quarters, the c ...

EXHIBIT 99.1 Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance -- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass., October 30, 2024 – Blueprint Medicines Corporation (Nasdaq: BPMC) tod ...

-- Achieved $128.2 million in AYVAKIT net product revenues in the third quarter 2024 -- -- Raising AYVAKIT net product revenue guidance to $475 million to $480 million for 2024 -- -- On track to initiate the registration-enabling HARBOR Part 2 study of elenestinib in ISM by year end -- CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the third quarter ended Sept 30, 2024, and provided updated finan ...